These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21451962)

  • 1. Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models.
    Xu XS; Wang H; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2011 Jun; 38(3):353-67. PubMed ID: 21451962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation.
    Wang AF; Ayyar VS
    J Pharm Sci; 2024 Jan; 113(1):191-201. PubMed ID: 37884193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fast method for testing covariates in population PK/PD Models.
    Khandelwal A; Harling K; Jonsson EN; Hooker AC; Karlsson MO
    AAPS J; 2011 Sep; 13(3):464-72. PubMed ID: 21725709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed logistic indirect response models: realization of oscillating behavior.
    Koch G; Schropp J
    J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):49-58. PubMed ID: 29313194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feedback control indirect response models.
    Zhang Y; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):343-58. PubMed ID: 27394724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing dynamics: Time-varying autoregressive models using generalized additive modeling.
    Bringmann LF; Hamaker EL; Vigo DE; Aubert A; Borsboom D; Tuerlinckx F
    Psychol Methods; 2017 Sep; 22(3):409-425. PubMed ID: 27668421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society.
    Cavero I
    Expert Opin Drug Saf; 2007 Jul; 6(4):465-71. PubMed ID: 17688390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D-optimal designs for parameter estimation for indirect pharmacodynamic response models.
    Khinkis LA; Krzyzanski W; Jusko WJ; Greco WR
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):523-39. PubMed ID: 19904585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinearity detection: advantages of nonlinear mixed-effects modeling.
    Jonsson EN; Wade JR; Karlsson MO
    AAPS PharmSci; 2000; 2(3):E32. PubMed ID: 11741248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latent variable indirect response modeling of categorical endpoints representing change from baseline.
    Hu C; Xu Z; Mendelsohn AM; Zhou H
    J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):81-91. PubMed ID: 23275019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population PK/PD analysis of metformin using the signal transduction model.
    Chae JW; Baek IH; Lee BY; Cho SK; Kwon KI
    Br J Clin Pharmacol; 2012 Nov; 74(5):815-23. PubMed ID: 22380769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.
    Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):635-55. PubMed ID: 16941234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonlinear dynamics and chaos theory: concepts and applications relevant to pharmacodynamics.
    Dokoumetzidis A; Iliadis A; Macheras P
    Pharm Res; 2001 Apr; 18(4):415-26. PubMed ID: 11451026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty.
    Mager DE; Mascelli MA; Kleiman NS; Fitzgerald DJ; Abernethy DR
    J Pharmacol Exp Ther; 2003 Dec; 307(3):969-76. PubMed ID: 14534354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis.
    Gobburu JV; Chen EP
    J Pharm Sci; 1996 May; 85(5):505-10. PubMed ID: 8742942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semiparametric mixed-effects analysis of PK/PD models using differential equations.
    Wang Y; Eskridge KM; Zhang S
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):443-63. PubMed ID: 18781382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.